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740A Commentary on the
SPARC StudyWe read with interest the recent report by members of
the SPARC (Study of Myocardial Perfusion and Coro-
nary Anatomy Imaging Roles in Coronary Artery
Disease) Study (1). The authors found, on the basis of
their interpretation of the results, that “costs were
signiﬁcantly lower after using SPECT rather than CTA
or PET” and concluded that “SPECT was econom-
ically attractive compared with PET” and hence the
preferred noninvasive test in patients with suspected
coronary artery disease (CAD) (1). Our observations of
the data from both the original study report (2) and
the more recent report (1) differ considerably.
First, the authors’ primary assumption was that
patients referred for all 3 modalities had sim-
ilar baseline characteristics. We would challenge
that assumption; both of us have been involved in
robust single-photon emission computed tomography
(SPECT) and positron emission tomography (PET)
programs, and one of us was involved in the recruit-
ment of patients for this study. It is well known
that for laboratories that perform both modalities,
patients with a higher suspicion of CAD are referred
to the PET laboratory because of the greater diag-
nostic accuracy and fewer false-positive studies. This
appears to be conﬁrmed in the SPARC Study; the
patients who underwent PET differed with respect
to diagnoses of diabetes, dyslipidemia, and hyperten-
sion as well as body mass index. A higher suspicion of
CAD would also result in more abnormal studies. In
fact, this was conﬁrmed by the SPARC data published
in 2012 (2); in that report, 22% of the SPECT studies
were abnormal, compared with 38% for PET and 18%
for computed tomography angiography (CTA). The
differences were statistically signiﬁcant. Not surpris-
ingly, the outcomes of the patient groups also differed.
In the most recent report (1), this translated into
higher mortality in the PET group than in the SPECT
group (5.5% vs. 1.6%) and a lower frequency of deaths
in the CTA group (0.7%). Thus, on the basis of the
data from both reports (1,2), we conclude that the
patients referred for PET were at signiﬁcantly higher
risk for both CAD and subsequent cardiac events
than the patients referred for SPECT or CTA.
Second, pharmacological stress testing was the
stress modality for all patients referred for PET and
28% of the patients referred for SPECT. This is
important for 2 reasons. Previous studies, including
those by Shaw and Iskandrian (4) and Navare et al. (5),
have shown that the prognosis is worse for patientswith both normal and abnormal results who are unable
to exercise. Thus, the higher mortality rate in the PET
group is not unexpected. Also, because all patients
undergoing PET were pharmacologically stress tested,
it would be assumed that, because of their limitations,
their symptoms could not be manifest with exercise.
Thus, the pre-test likelihood of CAD could have
been seriously misrepresented in this group because it
was unknown whether they had symptoms during
exercise. Therefore, they would fall into a lower clas-
siﬁcation of atypical or nonanginal when perhaps they
represented a higher CAD risk category.
Third, a higher frequency of abnormal perfusion
studies, as observed in the PET group, would translate
into more downstream testing. The SPARC data
conﬁrm this, because the referral rate of patients with
normal and abnormal studies was similar between PET
and SPECT. Thus, the rate of downstream testing, and
for that matter revascularization, was signiﬁcantly
higher because of the higher percentage of abnormal
results, particularly in themoderate to severe category.
This meets appropriate guidelines for further testing
and the desire to prevent possible unfavorable out-
comes. Because of the low number of patients enrolled
in each group, this study could not answer questions
such as the best modality for long-term beneﬁt.
Finally, the level of radiation exposure with PET
was substantially less than that with SPECT and CTA.
In SPARC, the level of radiation exposure was 6 mSv,
11.6 mSv, and 15.1 mSv for PET, SPECT, and CTA,
respectively. In the interest of reducing the level
of radiation exposure to patients (6), we maintain that
the beneﬁts of the radiopharmaceutical properties of
PET should be recognized as an important feature.
Although we agree with the authors that SPECT was
less expensive than PET or CTA in SPARC, we conclude
that downstream testing for PET is the best choice
given the higher percentage of abnormal studies and
more patients with CAD. In view of the higher diag-
nostic accuracy and less radiation exposure with PET
compared with SPECT shown in multiple studies, we
believe this imaging modality is appropriate and in the
interest of best patient care. The limitations of this
study with regard to CTA were addressed in an
editorial by Villines and Min (7).*Justin B. Lundbye, MD
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63:1009–10.REPLY: A Commentary on the SPARC StudyWe appreciate the interest of Drs. Lundbye and
Heller in our paper (1). They are concerned about the
selection of patients for computed tomography angi-
ography, positron emission tomography, and single-
photon emission computed tomography, because
there were many differences in the baseline charac-
teristics of these groups. The baseline characteristics
listed in Table 1 of our paper are for the entire
study population, not the propensity score–matched
patients used to compare the outcomes. The charac-
teristics of the matched patients (Table 3 in our
paper) are quite similar. Although propensity score
matching may not fully adjust for patient selection,
it largely corrects for the imbalances in baseline
characteristics.*Mark Hlatky, MD
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Again Results in Better
Patient OutcomesThe SPARC (Study of Myocardial Perfusion and Coro-
nary Anatomy Imaging Roles in Coronary Artery
Disease) Study by Hlatky et al. (1) is the latest of mul-
tiple studies showing improved outcomes with use of
computed tomography angiography (CTA). Although
this may not be surprising, because neither single-
photon emission computed tomography (SPECT) nor
positron emission tomography can detect subclinical
atherosclerosis, it is understated in the current paper.
The 2-year event rate for nonfatal myocardial infarc-
tion (MI) and death, a standard hard endpoint for
many studies, was 1% (6 of 590) for CTA, 2.8% (16 of
565) for SPECT, and 6.6% (36 of 548) for positron
emission tomography (p < 0.001), favoring CTA. This
was meaningful in absolute terms as well, represent-
ing a number needed to scan of only 55 for CTA
over SPECT and 18 for CTA over positron emission
tomography to prevent one MI or death. The cost-
effectiveness per life year saved was also quite low at
$10,700 per life year added. Furthermore, the median
(interquartile range) cost of care for CTA and SPECT
was virtually identical at $2,820 ($1,777 to $4,585) for
CTA and $2,810 ($1,692 to $4,436) for SPECT.
The results of SPARC are highly concurrent with a
much larger observation by Shreibati et al. (2). They
demonstrated that compared with stress myocardial
perfusion imaging, coronary CTAwas associatedwith a
40% reduction (odds ratio: 0.60; 95% conﬁdence
interval [CI]: 0.37 to 0.98; p ¼ 0.04) in acute MI after
multivariable adjustment. The study, which was
limited to 180 days of follow-up, included 8,820
patients undergoing CTA and 132,343 patients under-
going myocardial perfusion imaging. Despite the short
follow-up period, an 18% (nonsigniﬁcant) reduction in
all-cause mortality (1.05% for CTA vs. 1.28% for myo-
cardial perfusion imaging; p ¼ 0.32) was also shown.
This beneﬁt of CTA as compared with functional
testing was evaluated in a meta-analysis of CTA and
functional testing for diagnosis and outcomes (3). The
combined results of 11 studies including 1,575 patients
showed a higher diagnostic sensitivity for CTA versus
exercise electrocardiography and SPECT (98% [95%
CI: 93% to 99%] vs. 67% [95% CI: 54% to 78%] [p <
0.001] and 99% [95% CI: 96% to 100%] vs. 73% [95%
CI: 59% to 83%] [p ¼ 0.001], respectively). The spec-
iﬁcity of CTA was 82% (95% CI: 63% to 93%) versus
46% (95% CI: 30% to 64%) (p < 0.001) for exercise
